Relatlimab
As of the edition of 20 October 2026, Relatlimab is an antibody: marketed, first approved in 2022 (US); acts on LAG3; US protection ends in 2034.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Antibody
- Brand name
- Opdualag
- First approved
- 18 March 2022 (US)
- Approvals on record
- 4 in 4 regions
- Holder of the most recent approval
- Bristol Myers Squibb
- Registered trials
- 90, 13 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Digestive system; Blood and lymph; Nervous system; Immune system
US protection
US protection ends in 2034.
US protection ends in 2034, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Bristol Myers Squibb. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Relatlimab.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| LAG3 | Lymphocyte activation gene 3 protein | P18627 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 2 | 1 | 0 |
| Phase 1 | 13 | 6 | 4 | 2 |
| Phase 2 | 65 | 18 | 35 | 9 |
| Phase 3 | 6 | 0 | 4 | 2 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 90 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Applicant and Lead sponsor of trials | 2017 to now |